Characterization of HER2-positive breast cancer in patients treated at a hospital in Managua: A case series
DOI:
https://doi.org/10.62407/zeenc987Keywords:
Breast cancer, HER2 positive, risk factorsAbstract
Objective: To characterize HER2-positive breast cancer in patients treated at the Oncology unit of the Hospital Carlos Roberto Huembes between June 2016 and June 2022. Materials and Methods: Observational, descriptive, case series study, with a sample of 44 patients diagnosed with HER2 breast cancer. Information was obtained from clinical records and analyzed using IBM SPSS version 27 software. Results: 40.9% of the patients were between 51 and 60 years old, 97.7% were from urban areas, and 34.4% were overweight. Only 4.5% had a personal history of breast cancer, while 25% reported a family history. 63.6% of the cases corresponded to the Luminal B subtype, and only 34.6% were classified as pure HER2+. 34.1% were found in clinical stage IIA, and invasive ductal carcinoma predominated in 81.8% of the cases. Metastasis was not documented in 70.5%, with visceral metastases being the most common among those who presented with them. 100% of the patients underwent surgery, followed by biological therapy and chemotherapy. Currently, 40.9% are in treatment, 38.7% are under surveillance, and only 27.5% have died. Conclusion: Historically, HER2+ breast cancer has been associated with unfavorable prognoses due to diagnoses at advanced stages. However, in this study, patients were diagnosed at early stages, which, along with therapies targeted against HER2, is related to a better therapeutic response and an increase in survival.
Downloads
References
Fernández, J., Palacios, P., Cebey, V., Cortegoso, A. & López, R. (2021). Cáncer de mama. Medicine, 13(27), 1506-17. https://www.medicineonline.es/es-cancer-mama-articulo-S0304541221000445.
García-Pérez, R., Llanes-García, L., Agüero-Arboláez, M., Sánchez-Hernández, L., Franco-Rodón, A. & Alfonso-González, C. P. (2022). Carcinoma mamario HER2 positivo. Acta médica del centro, 16(3), 504-515. http://scielo.sld.cu/pdf/amdc/v16n3/2709-7927-amdc-16-03-504.pdf.
González, J., Morales, M., López, Z. & Díaz, M. (2011). Factores pronósticos del cáncer de mama. Revista Cubana de Cirugía, 50(1), 130-138.
Gutiérrez, C. & Schiff, R. (2011). HER2: Biology, detection and clinical implications. Archives of Pathology & Laboratory Medicine, 135(1), 55–62. https://doi.org/10.1043%2F2010-0454-RAR.1.
Harbeck, N., Penault-Llorca, F., Cortés, J., Gnant, M., Houssami, N., Poortmans, P., Ruddy, K., Tsang, J. & Cardoso, F. (2019). Breast cancer. Nature Reviews. Disease Primers, 5(1), 1-31. https://doi.org/10.1038/s41572-019-0111-2.
Hernández- López. E, Pellecer. J, Güity. R, Ramírez. C, Sosa. A, Morales. R, Letona. N, Barrios. N, Barrios. K & Rodas-Pernillo. O. (2021). Caracterización clínica, morfológica e inmunohistoquímica en Guatemala. Revista Médica, Colegio de Médicos y Cirujanos de Guatemala, 160(3), 224-230. https://doi.org/10.36109/rmg.v160i3.411.
Johnson, K., Conant, E. & Scott Soo, M. (2020). Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. Journal of Breast Imaging, 3(1), 12-24.doi: 10.1093/jbi/wbaa110.
Larios, M. (2017). Comportamiento clínico patológico del cáncer de mama en pacientes atendidas en el Hospital Escuela Carlos Roberto Huembes en el periodo de enero 2011- diciembre 2015. [Tesis de posgrado, Universidad Nacional Autónoma de Nicaragua-Managua]. Otra thesis, Universidad Nacional Autónoma de Nicaragua, Managua. http://repositorio.unan.edu.ni/id/eprint/7382.
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021). Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated Review. Cancers, 13(17), DOI:42-87.10.3390/cáncer13174287
Luna, N. (2019) Perfil molecular del Cáncer de Mama en pacientes del servicio de oncología del Hospital Carlos Roberto Huembes, período enero 2015, enero 2018. [Tesis de posgrado, Universidad Nacional Autónoma de Nicaragua-Managua]. https://repositorio.unan.edu.ni/16027/.
Madrigal, A., & Mora, B. (2018). Generalidades de cáncer de mama para médico general. Medicina Legal de Costa Rica, 35(1), 44-51. https://www.binasss.sa.cr/ojssalud/index.php/mlcr/article/view/81
Organización Panamericana de la Salud. (2023). Cáncer de mama (Informe). Organización Panamericana de la Salud. https://www.paho.org/es/temas/cancer-mama
Ramos, R., Pérez, B., Silva, R., Muñoz, M., Espinoza, W. & Cabezas, S. (2021). Caracterización de pacientes con cáncer de mama atendidas en Hospital Bertha Calderón Roque, Managua-Nicaragua. Revista Ciencias de la Salud y Educación Médica, 3(4). https://revistacienciasmedicas.unan.edu.ni/index.php/rcsem/article/view/96/79.
Rodríguez-Brenes, I., Komarova, N. & Wodarz, D. (2013) Tumor growth dynamics: insights into evolutionary processes, Trends in ecology & evolution, 28(10), 597–604. https://doi.org/10.1016/j.tree.2013.05.020
Selva, X. (2019). Evolución de pacientes con cáncer de mama HER2 positivo del Hospital Bertha Calderón 2016-2017. [Tesis de posgrado, Repositorio Universidad Nacional Autónoma de Nicaragua-Managua] https://repositorio.unan.edu.ni/id/eprint/11148/1/100026.pdf
Valle-Solís, A., Miranda-Aguirre, A., Mora-Pérez, J., Pineda-Juárez, J., Gallardo-Valencia, L., Santana, L., Cervantes-Sánchez, G. & Cárdenas-Cárdenas, E. (2019) Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo. Gaceta Médica de México, 155(1), 50-55. https://www.scielo.org.mx/pdf/gmm/v155s1/0016-3813-gmm-155-suppl1-S50.pdf
Taneja, P., Maglic, D., Kai, F., Zhu, S, Kending, R., Fry, E. & Inoue, K. (2010). Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clinical Medicine Insights: Oncology, 20(4), 15-34. 10.4137/cmo.s4773. https://journals.sagepub.com/doi/pdf/10.4137/CMO.S4773.
World Health Organization (WHO) (2019). WHO Classification of Tumors of the Breast (5th. ed.). International Agency for Research on Cancer.E. (2019) Supervivencia en cáncer de mama por subtipo mediante inmunohistoquímica: Un estudio retrospectivo. Gaceta Médica de México, 155(1), 50-55. https://www.scielo.org.mx/pdf/gmm/v155s1/0016-3813-gmm-155-suppl1-S50.pdf
Taneja, P., Maglic, D., Kai, F., Zhu, S, Kending, R., Fry, E. & Inoue, K. (2010). Classical and Novel Prognostic Markers for Breast Cancer and their Clinical Significance. Clinical Medicine Insights: Oncology, 20(4), 15-34. 10.4137/cmo.s4773. https://doi.org/10.4137/cmo.s4773
World Health Organization (WHO) (2019). WHO Classification of Tumors of the Breast (5th. ed.). International Agency for Research on Cancer. Consejo Editorial de la Clasificación de Tumores de la OMS. ISBN-13 78-92-832-4500-1
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Revista de Ciencias de la Salud de la Universidad Americana
This work is licensed under a Creative Commons Attribution 4.0 International License.
